PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: A National Cancer Institute experience

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Merola, Roberta ^a   Tomao, Luigi ^a,b   Antenucci, Anna ^a   Sperduti, Isabella ^a   Sentinelli, Steno ^a   Masi, Serena ^a   Mandoj, Chiara ^a   Orlandi, Giulia ^a   Papalia, Rocco ^a   Guaglianone, Salvatore ^a   Costantini, Manuela ^a   Cusumano, Giuseppe ^a   Cigliana, Giovanni ^a   Ascenzi, Paolo ^b   Gallucci, Michele ^a   Conti, Laura ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

Prostate cancer; Prostate cancer gene 3; Prostate specific antigen; Tumor aggressiveness; Urine and blood biomarkers

Indexed keywords

PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; ADULT; BLOOD; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84924214573     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0127-8     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013, 63(1):11-30.
2. Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, et al. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. 2009;28:135.
3. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res. 2012;31:32.
4. Sofra M, Antenucci A, Gallucci M, Mandoj C, Papalia R, Claroni C, et al. Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques. J Exp Clin Cancer Res. 2014, 33(1):63.
5. Croswell JM, Kramer BS, Crawford ED. Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park). 2011, 25(6):452-60. 463.
6. Croswell JM, Kramer BS, Crawford ED. Screening for prostate cancer with PSA testing: current status and future directions. Oncology. 2011, 25(6):452-60.
7. Matlaga BR, Eskew LA, McCullough DL. Prostate biopsy: indications and technique. J Urol. 2003, 169(1):12-9.
8. Raja J, Ramachandran N, Munneke G, Patel. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol. 2006, 61(2):142-53.
9. Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU Int. 2010, 105(2):166-9.
10. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59(23):5975-9.
11. Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2011, 301(1):1-6.
12. Luo Y, Gou X, Huang P, Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl. 2014, 16(3):487-92.
13. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360(13):1310-9.
14. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009, 360(13):1320-8.
15. Fall K, Garmo H, Andrèn O, Bill-Axelson A, Adolfsson J, Adami HO, et al. Scandinavian Prostate Cancer Group Study No. 4. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007, 99(7):526-32.
16. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, et al. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol. 2010, 28(6):677-80.
17. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011, 60(5):1045-54.
18. Montironi R, Mazzucchelli R, Lopez-Beltran A, Scarpelli M, Cheng L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU Int. 2011, 108(9):1394-401.
19. Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8-16.
20. Van Gils MP, Hessels D, van Hooij O, Jannink SA, PeelenWP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2008, 13(3):939-43.
21. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008, 54(5):1081-8.
22. Bollito E, De Luca S, Cicilano M, Passera R, Grande S, Maccagnano C, et al. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy. Anal Quant Cytol Histol. 2012, 34(2):96-104.
23. Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol. 2013, 34(3):1337-47.
24. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013, 190(1):64-9.
25. Goode RR, Marshall SJ, Duff M, Chevli E, Chevli KK. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. 2013;73:48-53.
26. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012, 109(3):360-6.
27. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011, 59(1):61-71.
28. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011, 29(10):1335-41.
29. van den Bergh RC, Giannarini G. Prostate cancer: surgery versus observation for localized prostate cancer. Nat Rev Urol. 2014, 11(6):312-3.
30. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010, 70(1):10-6.
31. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 2012, 110(1):43-9.
32. Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. 2011, 29(5):683-8.
33. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011, 59(1):96-105.
34. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008, 179(5):1804-9.